Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Antithrombotic therapy in patients with acute coronary syndromes Levine GN; Ali MN; Schafer AIArch Intern Med 2001[Apr]; 161 (7): 937-48The potential armamentarium of agents used in the treatment of acute coronary syndromes continues to expand, including such well-tested agents as aspirin, unfractionated heparin, and earlier-generation fibrinolytic agents, and newer agents such as low-molecular-weight heparins, direct thrombin inhibitors, thienopyridines, platelet glycoprotein IIb/IIIa receptor inhibitors, and bolus-administration fibrinolytic agents. Older and newer antithrombotic agents have undergone and continue to undergo intensive clinical investigation in patients with the clinical spectrum of acute coronary syndromes, which includes unstable angina, non-Q-wave (non-ST-segment elevation) myocardial infarction, and ST-segment elevation myocardial infarction. These studies, often conducted on an international scope and involving thousands of patients, provide data allowing practitioners to optimize the care of patients with acute coronary syndromes. In this article, studies of these established and newer agents in the treatment of patients with acute coronary syndromes are reviewed critically and summarized. Recommendations regarding use of antithrombotic agents in patients with acute coronary syndromes are then given.|Acute Disease[MESH]|Angina Pectoris/*drug therapy/mortality[MESH]|Coronary Disease/*drug therapy/mortality[MESH]|Drug Therapy, Combination[MESH]|Fibrinolytic Agents/pharmacology/*therapeutic use[MESH]|Heparin/therapeutic use[MESH]|Humans[MESH]|Incidence[MESH]|Myocardial Infarction/*drug therapy/mortality[MESH]|Platelet Aggregation Inhibitors/pharmacology/*therapeutic use[MESH]|Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors[MESH]|Practice Guidelines as Topic[MESH]|Survival Analysis[MESH]|Thrombin/antagonists & inhibitors[MESH]|Treatment Outcome[MESH] |
